TABLE 3.
Clinical cure, mortality and culture conversiona
| Clinical cure, mortality and culture conversion | Description |
|---|---|
| Clinical cure at EOT (n = 53) | 27 (50.9) |
| Culture conversion in patients with fungal species isolation (n = 44) | |
| Culture conversion at EOT | 17 (38.6) |
| Fungal persistence at EOT | 15 (34.1) |
| Cultures were not performed at EOT | 12 (27.3) |
| Deceased patients at EOT (n = 53) | |
| Deceased patients at EOT | 15 (28.3) |
| Deceased patients at 90 days after EOT | 24 (45.3) |
| Bacterial infection | 7 (30.4) |
| CLAD | 5 (20.8) |
| SARS-CoV-2 infection | 4 (16.7) |
| Fungal infection | 3 (12.5) |
| Relapse of pretransplant disease | 2 (8.3) |
| Hypovolemic shock | 2 (8.3) |
| Lung neoplasm | 1 (4.2) |
| Patients deceased in ICU | 14 (58.3) |
a
Data are expressed as numbers (%) unless otherwise indicated. CLAD, chronic lung allograft disease; EOT, end of treatment; ICU, intensive care unit.